Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018
Open accessThe DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet; 16 of the 32 sources its claims cite were checked for support.
Abstract
BACKGROUND: Fungal infections are responsible for >1.5 million deaths globally per year, primarily in those with compromised immune function. This is concerning as the number of immunocompromised patients, especially in those without human immunodeficiency virus (HIV), has risen in the past decade. The purpose of this analysis was to provide the current prevalence and impact of fungal disease in the United States. METHODS: We analyzed hospital discharge data from the most recent (2018) Healthcare Cost and Utilization Project National Inpatient Sample, and outpatient visit data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Costs are presented in 2018 United States (US) dollars. RESULTS: infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs. Most fungal disease occurred in patients with elevated risk of infection. The visit costs, lengths of stay, and risks of mortality in this population were more than twice that of those without fungal diagnoses. A further 6.6 million fungal infections were diagnosed during outpatient visits. CONCLUSIONS: Fungal disease is a serious clinical concern with substantial healthcare costs and significant increases in morbidity and mortality, particularly among predisposed patients. Increased surveillance, standardized treatment guidelines, and improvement in diagnostics and therapeutics are needed to support the rising numbers of at-risk patients.
Verified 2026-11-19 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
In 2018, an estimated 666,235 fungal infections were diagnosed during 35.5 million US inpatient visits, with an estimated attributable cost of $6.7 billion and a further 6.6 million fungal infections diagnosed in outpatient visits. Fungal diagnoses were associated with roughly doubled visit costs, lengths of stay, and mortality risk, especially in patients with predisposing conditions.
Key findings
- Among 35.5 million inpatient visits in 2018, 666,235 fungal infections were diagnosed; Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of diagnosed fungal infections and 81.1% of associated costs.
- The mean cost of an inpatient visit with a fungal diagnosis was $55,418 versus about $24,560 for an average inpatient visit; total costs for all visits with any fungal diagnosis were $37.7 billion, while visits with fungal disease as the primary cause totaled $1.4 billion.
- Approximately 32,560 deaths occurred in patients with any fungal diagnosis, and about 1,440 deaths occurred in patients admitted for fungal infections; highest mortality was seen with mucormycosis (18.6%) and invasive candidiasis (17.0%).
- In at-risk patients, fungal infection was associated with doubled average cost ($59,490 vs $29,700), doubled length of stay, and increased mortality risk; low-risk patients had fewer fungal infections (123,235; 18.50%) but at least as severe impacts.
Methods
- Analyzed 2018 Healthcare Cost and Utilization Project National Inpatient Sample hospital discharge data and 2016–2018 National Ambulatory Medical Care Survey / National Hospital Ambulatory Medical Care Survey outpatient visit data.
- Used ICD-10 codes to identify fungal infections and at-risk conditions, APR-DRG severity and mortality risk measures, and Elixhauser Comorbidity Index codes; costs are presented in 2018 US dollars using NIS cost-to-charge ratios.
- Statistical analyses were performed with SAS version 9.4; maps were generated with Datawrapper and presented by region rather than state per HCUP guidelines.
Limitations
- The paper states the true burden is likely greater than estimated: only half of invasive fungal infections are diagnosed before death, HCUP and NAMCS/NHAMCS cannot identify unique patients so prevalence rather than incidence is captured, and average costs and mortality may be underestimated because multiple visits may belong to one patient.
- The paper also notes NAMCS/NHAMCS may underestimate outpatient fungal infections because laboratory-test diagnoses may not be captured on the visit day, the 2014 comparison used ICD-9-CM while 2018 used ICD-10-CM, many cases were coded as “unspecified mycoses,” and procedures such as surgeries or central venous catheters were not incorporated as risk conditions.
- Evident from the text: reliance on administrative diagnosis codes may misclassify or undercount infections, and some “low-risk” patients may have unlisted risk conditions or procedures not captured in the dataset.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
12 Valid · 1 Not valid · 14 Not checked · 108 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“more than 1.5 times that of the costs reported 4 years prior [26].”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > DISCUSSION
What the sources say
- Disputedcites [26] Benedict, 2019, Estimation of direct healthcare costs of fungal diseases in the United States., Clin Infect Dis sourceExperimental — accuracy not yet measured
The Abstract Results report fungal-disease costs of more than $7.2 billion, not an amount less than $6.6 billion. Thus $6.6 billion cannot be more than 1.5 times the cost reported by this paper. The Discussion likewise describes annual costs as more than $7 billion (page unavailable in our copy). (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fungal infections can further complicate chronic conditions and nonfungal infections, reported in patients with asthma [12], cirrhosis [13], chronic obstructive pulmonary disease (COPD) [14], diabetes [15, 16], cystic fibrosis (CF) [17, 18], tuberculosis [19], and influenza [20, 21].”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > Abstract > Conclusions
What the sources say
- Supportedcites [12] Denning, 2006, The link between fungi and severe asthma: a summary of the evidence., Eur Respir J source
Citation [12] supports the asthma example, not the other conditions, which have separate citations. The “Chronic exposure to fungi as a driver for asthma?” section links chronic fungal infection with asthma and notes improvement after antifungal treatment; “ANTIFUNGAL THERAPY” likewise reports improved asthma in patients treated for fungal infection. Page numbers are not available in the supplied passages. (LLM, conf=0.86)
- Partly supportedcites [13] Pilmis, 2016, New clinical phenotypes of fungal infections in special hosts., Clin Microbiol Infect sourceExperimental — accuracy not yet measured
Our copy of Pilmis et al. supports only the cirrhosis element of the list: the Liver Disease section states 'Patients with cirrhosis are at increased risk for bacterial and fungal infections' with an overall IFD incidence of 1% and spontaneous fungal peritonitis accounting for 3.5% of infectious peritonitis, and Table 1 (Conclusions) lists 'Liver disease (cirrhosis) | Spontaneous fungal peritonitis'. The paper's scope is primary immunodeficiencies (CARD9, STAT1, STAT3/HIES, CGD), TNF-alpha blocker therapy, burns and cirrhosis (Introduction, Abstract). No passage mentions asthma, COPD, diabetes, cystic fibrosis, tuberculosis or influenza (searched: asthma/COPD/cystic fibrosis/diabetes/influenza/tuberculosis), so those six attributions are not supported by this source. (LLM, conf=0.75)
- Supportedcites [14] Morris, 2008, Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease., Clin Infect Dis source
Citation [14] is attached to COPD, not to the other conditions listed. The Abstract reports that Pneumocystis, a fungal pathogen, is commonly found in patients with COPD; the Discussion says its colonization might worsen airway obstruction, while noting that causation was not established. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the 4-year span from the 2014 HCUP dataset analyzed by Benedict et al [26] to the 2018 data analyzed here, the total direct costs (all primary and invasive infections; adjusted for inflation) of fungal infections in inpatient visits nearly doubled from 3.9 million to 6.7 million USD (Figure 2, Supplementary Table 1).”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > RESULTS > Fungal Disease Costs in Inpatient Visits
What the sources say
- Supportedcites [26] Benedict, 2019, Estimation of direct healthcare costs of fungal diseases in the United States., Clin Infect Dis source
The Methods (Data sources; page unavailable) state that Benedict et al. used the 2014 HCUP National Inpatient Sample to estimate US fungal disease-associated hospitalizations. The citation identifies the 2014 dataset they analyzed; the comparison with the citing authors’ 2018 data is the citing authors’ own analysis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the 4-year span since 2014 [26], the overall number of fungal infections deemed directly responsible for hospitalization, either listed as cause for admission or as having an invasive presentation of disease, moderately increased.”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > DISCUSSION
What the sources say
- Supportedcites [26] Benedict, 2019, Estimation of direct healthcare costs of fungal diseases in the United States., Clin Infect Dis source
The citation follows “since 2014,” and the Methods (Data sources) state that the paper used 2014 national inpatient data to estimate fungal-disease hospitalizations. The Methods (Disease groupings and exclusion criteria) also match the citing sentence’s criteria: a principal fungal-disease diagnosis or an invasive fungal disease listed anywhere on the record. The later increase is the citing authors’ comparison, not a trend attributed to this source. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“although the increasing frequency of antifungal resistant- and non-albicans species may play a role [35].”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > DISCUSSION
What the sources say
- Partly supportedcites [35] Lockhart, 2012, Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011., J Clin Microbiol sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports an increasing proportion of candidemia caused by non-albicans species, including C. glabrata and C. parapsilosis. It does not establish that this shift contributes to an increase in invasive candidiasis; it also reports that overall fluconazole resistance did not increase between surveillance periods. (LLM, conf=0.86)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
94 more claims
Create a free account to see all 135 claims and to verify the 4 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 13
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > DISCUSSION
“the number of Aspergillus infections diagnosed during inpatient visits decreased from 14 820 in 2014 to 9725 in 2018.”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > METHODS > Element Descriptions
“| Aspergillosis | B44 | 17 825 |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > METHODS > Element Descriptions
“| Kidney | T86.1 | 45 |”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > RESULTS > Aspergillosis
“| Kidney | 47.33 | 119.94 | 2.53 | 7.01 | 16.11 | 2.30 | 225285.88 | 4017.78 | 6.97 (5.21–9.17) | 85 650 |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > Abstract > Results
“Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs.”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > RESULTS > Diagnosis and Mortality Rates of Fungal Infections by Risk Condition
“Aspergillus, Candida, and Pneumocystis account for >80% of fungal infections diagnosed in hospitalized patients and the impacts are detailed below.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > RESULTS
“17.8 million (50.14%) of which had diagnoses associated with elevated risk of fungal infections (“at-risk”).”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > DISCUSSION
“there were 16.7 million hospitalizations of patients with comorbidities associated with increased risk of fungal disease”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > METHODS > Element Descriptions
“| Bone marrow | Z94.81 | 21 760 |”
§ Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018 > RESULTS > Aspergillosis
“| Bone marrow | 48.39 | 72.19 | 1.49 | 6.83 | 11.97 | 1.75 | 170781.25 | 4023.53 | 5.80 (4.35–7.57) | 1005 |”
10 more findings
Create a free account to see every finding of this check.
Citations
Cites
Comorbidity measures for use with administrative data.
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998) · Medical Care · doi:10.1097/00005650-199801000-00004 · Cited by 9,921 · cited 2×
“The role of comorbidities in patient outcome was further explored using the Elixhauser Comorbidity Index (ECI; Supplementary Table 3).”
MethodGlobal and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953 · cited 1×
“5 million deaths globally per year, primarily in those with some compromised immune function [1].”
BackgroundPappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570 · cited 2×
“Despite this decrease, the number of fungal infections has been steadily increasing over the past 10 years in patients without HIV [6], including individuals undergoing drug-induced immunosuppression associated with solid organ and stem cell transplantation [7], cancer treatments [8], and immunomodulators for autoimmu…”
BackgroundMasur, H., Michelis, M. A., Greene, J. B., Onorato, I., Vande Stouwe, R. A., Holzman, R. S., Wormser, G., Brettman, L., Lange, M., Murray, H. W., et al. (1981) · New England Journal of Medicine · doi:10.1056/nejm198112103052402 · Cited by 1,434 · cited 1×
“Within the United States (US), fungal infections, including those caused by Pneumocystis jirovecii, have historically been associated with the human immunodeficiency virus (HIV)/ AIDS epidemic as AIDS-defining illnesses [4].”
BackgroundHealthcare Cost and Utilization Project (HCUP)
(2016) · The SAGE Encyclopedia of Pharmacology and Society · doi:10.4135/9781483349985.n182 · Cited by 1,035
The link between fungi and severe asthma: A summary of the evidence
Denning, D. W., O'Driscoll, B. R., Hogaboam, C. M., Bowyer, P., & Niven, R. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00074705 · Cited by 824 · cited 1×
“Fungal infections can further complicate chronic conditions and nonfungal infections, reported in patients with asthma [12], cirrhosis [13], chronic obstructive pulmonary disease (COPD) [14], diabetes [15, 16], cystic fibrosis (CF) [17, 18], tuberculosis [19], and influenza [20, 21].”
BackgroundTrends in Mortality Due to Invasive Mycotic Diseases in the United States, 1980–1997
McNeil, M. M., Nash, S. L., Hajjeh, R. A., Phelan, M. A., Conn, L. A., Plikaytis, B. D., & Warnock, D. W. (2001) · Clinical Infectious Diseases · doi:10.1086/322606 · Cited by 657 · cited 1×
“As control of HIV/AIDS was substantially increased with the introduction of antiretroviral therapies, the number of associated fungal infections decreased [5].”
BackgroundEstimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438 · cited 5×
“In the 4-year span from the 2014 HCUP dataset analyzed by Benedict et al [26] to the 2018 data analyzed here, the total direct costs (all primary and invasive infections; adjusted for inflation) of fungal infections in inpatient visits nearly doubled from 3.”
BackgroundMethodInfluentialAmbulatory Surgery Data From Hospitals and Ambulatory Surgery Centers: United States, 2010.
Hall, M. J., Schwartzman, A., Zhang, J., & Liu, X. (2017) · PubMed · Cited by 405
Amin, R., Dupuis, A., Aaron, S. D., & Ratjen, F. (2010) · Chest · doi:10.1378/chest.09-1103 · Cited by 376 · cited 1×
“Fungal infections can further complicate chronic conditions and nonfungal infections, reported in patients with asthma [12], cirrhosis [13], chronic obstructive pulmonary disease (COPD) [14], diabetes [15, 16], cystic fibrosis (CF) [17, 18], tuberculosis [19], and influenza [20, 21].”
Background
Cited by
Items 201–224 of 224
Chavan, M., Bachhav, R. L., Sonavane, D. D., et al. (2026) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2026.00073
Okuno, M., Schwartz, E. L., Benedict, K., Massey, J., Boulware, D. R., Gold, J. A. W., & Bahr, N. C. (2026) · Medical Mycology · doi:10.1093/mmy/myag021
Liang, J., Xiong, G., Han, F., & Zhuge, S. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s573344
Steixner, S. J. M., Vahedi‐Shahandashti, R., Eisele, D., Ruppitsch, W., & Lass‐Flörl, C. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1771561
Human Dectin-1- and Dectin-2-targeted DectiSomes are effective against diverse pathogenic fungi
Ambati, S., Lin, X., Lewis, Z., PETER, J., & Meagher, R. B. (2026) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01689-25 · Cited by 2
Beyond roughness: Lateral surface architecture drives Candida albicans virulence on denture polymers
Montoya, C., Agrawal, C., Solanki, V., Dikin, D. A., Sousanieh, M., Su, F., & Orrego, S. (2026) · Dental Materials · doi:10.1016/j.dental.2026.04.030
Impact of Antifungal Medications on the Health of Pets: A Review
Abdullah, N. K., Al-Najmawi, T. K., abdulhameed, S. K., Alhafidh, N. M., Haddad, M. F., & Saadi, A. M. (2026) · Springer proceedings in earth and environmental sciences · doi:10.1007/978-3-032-18970-7_94
Júlio, A. A., Venancio, A. N., de Souza, G. R., da Silva, M. E. G., Parreira, L. A., Aytar, E. C., Ferreira, M. S., Caprini, H. O. G., Soares, M. G., Santos, M. F. C., et al. (2026) · Brazilian Journal of Microbiology · doi:10.1007/s42770-026-01964-2
Nadeb, M., Aghaei, S. S., Komeili-Movahed, T., & Afkhami, H. (2026) · Oxidative Medicine and Cellular Longevity · doi:10.1155/omcl/5525367
Haas, A. L., & Hanson, K. E. (2026) · Journal of Clinical Microbiology · doi:10.1128/jcm.01911-25
Warren, B. G., Graves, A., Barrett, A., Fils-Aime, G., Stiegel, M. A., Smith, B. A., Schwartz, I. S., & Anderson, D. J. (2026) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2026.10491
Smâdu, S., Tetradov, S. C., Popescu, C. P., Nica, M., Oprisan, C., Ene, L., & Florescu, S. A. (2026) · Journal of Fungi · doi:10.3390/jof12070482
Al-Nihmi, F. M. A., & Alserkal, E. A. A. (2026) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-026-05460-w
“Fungal pathogens constitute a significant and escalating challenge to global public health, with their clinical impact magnified by rising incidence rates and associated morbidity and mortality [1].”
Goel, A., Rishishwar, P., Rishishwar, S., et al. (2026) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2026.147101
Oworae, K. O., Rabacal, W., Hu, A., Wychrij, D. A., Rayens, E. A., Chapman, T. I., Bahl, J., & Norris, K. A. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01047-26
Self-citationFungal Infections in Disorders of Inborn Errors of Immunity
Dhaliwal, M., Thakur, V., Warris, A., Brown, G. D., Pilania, R. K., & Dambuza, I. M. (2026) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-026-09182-2 · Cited by 2
Identification of Invasive Aspergillosis in Electronic Health Records
Rayens, E. A., Skela, J., Ackerson, B. K., Pomichowski, M. E., Price, L. B., & Tartof, S. Y. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag478
“Invasive aspergillosis (IA) affects roughly 15 000 people in the United States every year, with millions more at risk [1, 2].”
Self-citationAntifungals: mechanism of action, resistance, and therapeutic perspectives
Gómez-Gaviria, M., & Mora-Montes, H. M. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108771
Achilonu, C. C. (2026) · Drugs and Drug Candidates · doi:10.3390/ddc5030047 · Cited by 2
Taş, E., Çetin, B., Yılmazer, A. N., & Işık, T. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12737-3
Suresh, A., Nidheesh, K. S., & Singh, S. K. (2025) · Awareness Journals · doi:10.67277/awj01-2025-000012 · Cited by 1
Pawar, S., Xue, H. H., Wang, S., Marras, S. A. E., & Xue, C. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01166-26
Pratiekauri, S., Mariana, N., Widiantari, A. D., et al. (2026) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/3527
Metadata
- Authors
- Rayens, E., & Norris, K. A.
- Affiliations
- University of Georgia (US)
- Corresponding author
- Rayens, Emily
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-01-01
- Volume
- 9
- Issue
- 1
- Pages
- ofab593-ofab593
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC8754384
- OpenAlex
- W4206237820
- Semantic Scholar
- cd7146be3019029e091b8da81d5fe7453659dd86
- Cited by
- 228
- References
- 40
- Citations by year
- 2026: 40 · 2025: 71 · 2024: 54 · 2023: 49 · 2022: 14
- FWCI
- 22.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1R01 AI148365-01A1)
- University of Georgia Research Foundation
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
- Keywords
- fungal infection, prevalence, healthcare burden, health care costs, hospitalization, outpatient visits, immunocompromised patients, mortality, length of hospital stay, risk factors, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.